Effectiveness and safety of clofazimine and pentoxifylline in type 2 lepra reaction: A double-blind, randomized, controlled study

International Journal of Dermatology

Volumn 54, Issue 11, 2015, Pages 1325-1332

  Roy, Kunal ^a   Sil, Amrita ^b   Das, Nilay K ^a   Bandyopadhyay, Debabrata ^a  

^a MEDICAL COLLEGE AND HOSPITAL   (India)

^b INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE; PENTOXIFYLLINE; PREDNISOLONE; LEPROSTATIC AGENT; PHOSPHODIESTERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EPIGASTRIC DISCOMFORT; ERUCTATION; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; ICHTHYOSIS; LEPROSY; MALE; PARALLEL DESIGN; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN DISCOLORATION; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; TYPE 2 LEPRA REACTION; COMPLICATION; INFLAMMATION; MICROBIOLOGY; MIDDLE AGED; NEURALGIA; REACTIVE ARTHRITIS; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ARTHRITIS, REACTIVE; CLOFAZIMINE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INFLAMMATION; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; NEURALGIA; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945474008     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/ijd.12793     Document Type: Article

References (17)

1. Debi B, Mohanty HC. Reactional states of leprosy: a clinical assessment. Lepr India 1977; 49: 229-233.
2. Sehgal VN, Rege VL, Mas carenhas MF. Pattern of reactions in leprosy: a clinical appraisal. Lepr India 1977; 49: 221-228.
3. Kaur I, Dogra S, Bhushan K. Epidemiological characteristics of leprosy reactions: 15 years' experience from North India. Int J Lepr Other Mycobact Dis 2004; 72: 125-133.
4. Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects. J Antimicrob Chemother 2012; 67: 290-298.
5. van Crevel R, Vonk AG, Netea MG, et al. Modulation of LPS-, PHA- and M. tuberculosis mediated cytokine production by pentoxifylline and thalidomide. Eur Cytokine Netw 2000; 11: 574-579.
6. Walker SL, Waters MFR, Lockwood DNJ. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007; 78: 197-215.
7. WHO Expert Committee on Leprosy. Technical Support Series 1998; 874: 1-48.
8. Schreuder AM, Naaf B. Chronic recurrent ENL, steroid dependent: long term treatment with high dose clofazimine. Lepr Rev 2003; 78: 386-389.
9. Kaur I, Dogra S, Narang T, De D. Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: a randomized study. Australas J Dermatol 2009; 50: 181-185.
10. Van Brakel WH, Nicholis PG, Lockwood DNJ, et al. A scale to assess the severity of leprosy reactions. Lepr Rev 2007; 78: 161-164.
11. Singh PC, Mishra S, Mishra M. Pentoxifylline in reactions in leprosy. Indian J Dermatol Venereol Leprol 1996; 62: 163-164.
12. Chatterjee M, Jaiswal AK. Does pentoxifylline find a place in the armementarium of leprologists in type II reaction? Indian J Lepr 2002; 74: 329-334.
13. Sales AM, de Matos HJ, Nery JA. Double-blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type II reaction in leprosy. Braz J Med Biol Res 2007; 40: 243-248.
14. Nery JA, Perissé AR, Sales AM, et al. The use of pentoxifylline in the treatment of type 2 reactional episodes in leprosy. Indian J Lepr 2000; 72: 457-467.
15. Burte NP, Chandorkar AG, Muley MP. Clofazimine in lepra (ENL) reaction, one year clinical trial. Lepr India 1983; 55: 265-277.
16. Bhasin DK, Kumar B, Broor SL, et al. Effect of clofazimine: detailed studies of small intestine functions. Indian J Lepr 1985; 57: 364-372.
17. Welsh O, Gómez M, Mancias C, et al. A new therapeutic approach to type II leprosy reaction. Int J Dermatol 1999; 38: 931-933.